Healthy VolunteersPhase 1NCT06831344

A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

A Phase 1 study testing Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water and Vonoprazan (Reference) in people with Healthy Volunteers, run by Phathom Pharmaceuticals, Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The primary objective of this study is to assess the bioavailability (BA) of a single oral dose of two vonoprazan orally disintegrating tablet formulations (ODT-1 or ODT-2) administered without water or mixed with water and administered via a syringe relative to the vonoprazan tablet in healthy participants. Read more about this study

Who is it for?: Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for: Healthy Volunteers
What is being tested?: Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water and Vonoprazan (Reference)
Type of treatment: Pill or oral medicine, Injection or infusion
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 25 participants
Where: 1 siteUnited States
Study dates: 14 Feb 2025to 10 Apr 2025
Phase: Phase 1
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 55 years
All sexes
Healthy volunteers accepted
Adult

Who may be able to join

The participant is 18 to 55 years of age, inclusive, at Screening.
The participant has a body mass index (BMI) 18 to 32 kg/m2, inclusive, at Screening.
The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead electrocardiogram (ECG) results, and physical examination findings at Screening.
Female participants of reproductive potential must use an acceptable method of birth control (ie, diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide, oral contraceptives, or abstinence) from signing the informed consent form (ICF) until 4 weeks after the last dose of study drug or be surgically sterile (ie, hysterectomy or bilateral oophorectomy) or postmenopausal (defined as amenorrhea for 12 consecutive months and documented plasma follicle stimulating hormone [FSH] level >40 IU/mL during Screening).
Female participants must have a negative pregnancy test at Screening and upon Check-in.
The participant agrees to comply with all protocol requirements.
The participant is able to provide written informed consent.

Who cannot join

The participant has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at Screening.
The participant has a positive test result for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Check-in.
The participant has a history of a clinically significant neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality that may impact the ability of the subject to participate.
The participant has current or recent (within 6 months) gastrointestinal conditions that would be expected to influence the absorption of drugs (eg, history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis (EE)), frequent (more than once per week) occurrence of heartburn, or any surgical intervention.
The participant has any other clinically significant findings on physical examination, clinical laboratory abnormalities, and/or ECG results that preclude his/her participation in the study, as deemed by the investigator.
The participant has used any prescription (excluding hormonal birth control) and/or over-the-counter medications (including Cytochrome P450 3A4 (CYP3A4) inducers) except acetaminophen (up to 2 g per day), including herbal or nutritional supplements, within 14 days before the first dose of study drug, and/or is expected to require any such medication during the course of the study until the end of confinement on Study Day 23.

Show all 17Show fewer

The participant has consumed grapefruit and/or grapefruit juice, Seville orange or Seville orange-containing products (eg, marmalade), or other food products that may be CYP3A4 inhibitors (eg, vegetables from the mustard green family [kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard] and charbroiled meats) within 7 days before the first dose of study drug and/or is expected to be unable to abstain through the study.
The participant has consumed caffeine- or xanthine-containing products within 48 hours (or 5 half-lives) before the first dose of study drug and/or is unable to abstain through the study.
The participant is a smoker and/or has used nicotine or nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6 months before the first dose of study drug.
The participant has a history of alcohol abuse and/or drug addiction within the last year or excessive alcohol consumption (regular alcohol intake >21 units per week for male subjects and >14 units of alcohol per week for female subjects; 1 unit is equal to approximately ½ pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure [25 mL] of spirits) or use of alcohol 48 hours before the first dose of study drug.
The participant has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at Screening or Check-in.
The participant is involved in strenuous activity or contact sports within 24 hours before the first dose of study drug and during the study.
The participant has donated blood or blood products >450 mL within 30 days before the first dose of study drug.
The participant has a history of relevant drug and/or food allergies (ie, allergy to vonoprazan or excipients or any significant food allergy that could preclude a standard diet in the clinical unit).
The participant has received a study drug in another investigational study within 5-times the t1/2 of the study drug or 30 days of dosing, whichever is longer.
Female participants who are pregnant or lactating; intend to become pregnant before, during, or within 4 weeks after participating in this study; or intend to donate ova during this time period.
The participant is not suitable for entry into the study in the opinion of the investigator.

Trial locations and contacts

1 site in 1 country.

United States1 site

7551 Metro Center Dr Ste 200
Austin, Texas, 78744

Other trials in United States

About this study

Official title: A Phase 1, Open-Label, Randomized, Single-Dose, 5-Period Crossover Study to Determine the Bioavailability of Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Subjects

Conditions: Healthy Volunteers
Being tested: Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference)
Keywords: Erosive Esophagitis, Non-erosive Gastroesophageal Reflux Disease, Vonoprazan

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Vonoprazan ODT-1 or ODT-2 without WaterDrug
Vonoprazan will be administered orally as an ODT-1 or ODT-2 without water
Vonoprazan ODT-1 or ODT-2 with WaterDrug
Vonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe
Vonoprazan (Reference)Drug
Vonoprazan will be administered orally as a tablet

Study groups in NCT06831344
Study group	Role	What they receive
Sequence A, B, C, D, E: Vonoprazan 10 mg	Experimental	Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period. Receives: Drug: Vonoprazan ODT-1 or ODT-2 without Water; Drug: Vonoprazan ODT-1 or ODT-2 with Water; Drug: Vonoprazan (Reference)
Sequence B, D, E, C, A: Vonoprazan 10 mg	Experimental	Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period. Receives: Drug: Vonoprazan ODT-1 or ODT-2 without Water; Drug: Vonoprazan ODT-1 or ODT-2 with Water; Drug: Vonoprazan (Reference)
Sequence C, E, B, A, D: Vonoprazan 10 mg	Experimental	Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period. Receives: Drug: Vonoprazan ODT-1 or ODT-2 without Water; Drug: Vonoprazan ODT-1 or ODT-2 with Water; Drug: Vonoprazan (Reference)
Sequence D, C, A, E, B: Vonoprazan 10 mg	Experimental	Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period. Receives: Drug: Vonoprazan ODT-1 or ODT-2 without Water; Drug: Vonoprazan ODT-1 or ODT-2 with Water; Drug: Vonoprazan (Reference)
Sequence E, A, D, B, C: Vonoprazan 10 mg	Experimental	Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period. Receives: Drug: Vonoprazan ODT-1 or ODT-2 without Water; Drug: Vonoprazan ODT-1 or ODT-2 with Water; Drug: Vonoprazan (Reference)

What is being measured

The primary outcome is the main question the study is designed to answer.

Maximum Observed Drug Concentration (Cmax) of Vonoprazan
Cmax of Vonoprazan was reported.
Measured: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan
AUC0-t of Vonoprazan was reported.
Measured: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan
AUC0-inf of Vonoprazan was reported.
Measured: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

Secondary outcomes (6)

Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan
Tmax of Vonoprazan was reported.
Measured: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan
Tlag of Vonoprazan was reported.
Measured: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Terminal Elimination Rate Constant (λz) of Vonoprazan
λz of Vonoprazan was reported.
Measured: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Terminal Phase Half-life (t1/2) of Vonoprazan
t1/2 of Vonoprazan was reported.
Measured: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Apparent Oral Clearance (CL/F) of Vonoprazan
CL/F of Vonoprazan was reported.
Measured: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Apparent Volume of Distribution (Vz/F) of Vonoprazan
Vz/F of Vonoprazan was reported.
Measured: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

14 Feb 202510 Apr 2025

First posted18 Feb 2025
Study start14 Feb 2025
Primary completion5 Apr 2025
Study completion10 Apr 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Healthy VolunteersStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 1
Primary purpose: Basic science
Allocation: Randomised
Intervention model: Crossover
Model description: The treatment periods will include administration of single doses of vonoprazan 10 mg on Day 1 of each period. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.
Masking: None (open label)
Enrolment: 25 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06831344
Sponsor's protocol ID: VPED-105
Status last verified: Dec 2025
First submitted: 14 Feb 2025
Last updated: 19 Dec 2025
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
RecruitingEarly Phase 1
Study Brain Mechanisms of Frustration With Magnetoencephalography in Healthy Volunteers
Irritability

All Healthy Volunteers trials

Study at a glance

From the registry record, last updated by the sponsor on 19 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase 1, Open-Label, Randomized, Single-Dose, 5-Period Crossover Study to Determine the Bioavailability of Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Subjects
ClinicalTrials.gov ID: NCT06831344
Acronym / sponsor ID: VPED-105
Conditions: Healthy Volunteers
Keywords: Erosive Esophagitis, Non-erosive Gastroesophageal Reflux Disease, Vonoprazan
Phase: Phase 1
Study type: Interventional
Recruitment status: Completed
Enrolment: 25 participants (actual)
Lead sponsor: Phathom Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
Study start: 14 Feb 2025 (actual)
Primary completion: 5 Apr 2025 (actual)
Study completion: 10 Apr 2025 (actual)
First posted: 18 Feb 2025 (actual)
Results: Posted 19 Dec 2025

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Basic science
Allocation: Randomised
Intervention model: Crossover
Masking: None (open label)
Number of arms: 5
Model description: The treatment periods will include administration of single doses of vonoprazan 10 mg on Day 1 of each period. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.

Arm	Type	Receives
Sequence A, B, C, D, E: Vonoprazan 10 mg	Experimental	Drug: Vonoprazan ODT-1 or ODT-2 without Water, Drug: Vonoprazan ODT-1 or ODT-2 with Water, Drug: Vonoprazan (Reference)Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.
Sequence B, D, E, C, A: Vonoprazan 10 mg	Experimental	Drug: Vonoprazan ODT-1 or ODT-2 without Water, Drug: Vonoprazan ODT-1 or ODT-2 with Water, Drug: Vonoprazan (Reference)Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.
Sequence C, E, B, A, D: Vonoprazan 10 mg	Experimental	Drug: Vonoprazan ODT-1 or ODT-2 without Water, Drug: Vonoprazan ODT-1 or ODT-2 with Water, Drug: Vonoprazan (Reference)Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.
Sequence D, C, A, E, B: Vonoprazan 10 mg	Experimental	Drug: Vonoprazan ODT-1 or ODT-2 without Water, Drug: Vonoprazan ODT-1 or ODT-2 with Water, Drug: Vonoprazan (Reference)Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.
Sequence E, A, D, B, C: Vonoprazan 10 mg	Experimental	Drug: Vonoprazan ODT-1 or ODT-2 without Water, Drug: Vonoprazan ODT-1 or ODT-2 with Water, Drug: Vonoprazan (Reference)Participants will be randomly assigned to 1 of 5 treatment sequences in a 1:1:1:1:1 ratio. On the first day of each dosing period, participants will receive 1 of the following study treatments according to the treatment sequence they are randomly assigned to: * Treatment A: Vonoprazan 10 mg ODT-1 without water * Treatment B: Vonoprazan 10 mg ODT-1 mixed with water and administered via a syringe * Treatment C: Vonoprazan 10 mg ODT-2 without water * Treatment D: Vonoprazan 10 mg ODT-2 mixed with water and administered via a syringe * Treatment E (reference): Vonoprazan 10 mg tablet. There will be a washout interval of a minimum of 5 days between study drug dosing in each period.

Who may qualify

Ages: 18 to 55 years
Sex: All
Healthy volunteers: Accepted
Age groups: Adult

Key inclusion criteria (7 listed)

The participant is 18 to 55 years of age, inclusive, at Screening.
The participant has a body mass index (BMI) 18 to 32 kg/m2, inclusive, at Screening.
The participant is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead electrocardiogram (ECG) results, and physical examination findings at Screening.
Female participants of reproductive potential must use an acceptable method of birth control (ie, diaphragm with spermicide, intrauterine device, condom with foam or vaginal spermicide, oral contraceptives, or abstinence) from signing the informed consent form (ICF) until 4 weeks after the last dose of study drug or be surgically sterile (ie, hysterectomy or bilateral oophorectomy) or postmenopausal (defined as amenorrhea for 12 consecutive months and documented plasma follicle stimulating hormone [FSH] level >40 IU/mL during Screening).
Female participants must have a negative pregnancy test at Screening and upon Check-in.

Key exclusion criteria (17 listed)

The participant has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at Screening.
The participant has a positive test result for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Check-in.
The participant has a history of a clinically significant neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality that may impact the ability of the subject to participate.
The participant has current or recent (within 6 months) gastrointestinal conditions that would be expected to influence the absorption of drugs (eg, history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis (EE)), frequent (more than once per week) occurrence of heartburn, or any surgical intervention.
The participant has any other clinically significant findings on physical examination, clinical laboratory abnormalities, and/or ECG results that preclude his/her participation in the study, as deemed by the investigator.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Vonoprazan ODT-1 or ODT-2 without WaterVonoprazan will be administered orally as an ODT-1 or ODT-2 without water	Drug	Sequence A, B, C, D, E: Vonoprazan 10 mg, Sequence B, D, E, C, A: Vonoprazan 10 mg, Sequence C, E, B, A, D: Vonoprazan 10 mg, Sequence D, C, A, E, B: Vonoprazan 10 mg, Sequence E, A, D, B, C: Vonoprazan 10 mg
Vonoprazan ODT-1 or ODT-2 with WaterVonoprazan will be administered orally as an ODT-1 or ODT-2 with water via a syringe	Drug	Sequence A, B, C, D, E: Vonoprazan 10 mg, Sequence B, D, E, C, A: Vonoprazan 10 mg, Sequence C, E, B, A, D: Vonoprazan 10 mg, Sequence D, C, A, E, B: Vonoprazan 10 mg, Sequence E, A, D, B, C: Vonoprazan 10 mg
Vonoprazan (Reference)Vonoprazan will be administered orally as a tablet	Drug	Sequence A, B, C, D, E: Vonoprazan 10 mg, Sequence B, D, E, C, A: Vonoprazan 10 mg, Sequence C, E, B, A, D: Vonoprazan 10 mg, Sequence D, C, A, E, B: Vonoprazan 10 mg, Sequence E, A, D, B, C: Vonoprazan 10 mg

Primary outcome

Maximum Observed Drug Concentration (Cmax) of Vonoprazan
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Cmax of Vonoprazan was reported.
Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
AUC0-t of Vonoprazan was reported.
AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
AUC0-inf of Vonoprazan was reported.

6 secondary outcomes

Time to Maximum Observed Plasma Concentration (Tmax) of Vonoprazan
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Time Until First Measurable Concentration in Plasma (Tlag) of Vonoprazan
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Terminal Elimination Rate Constant (λz) of Vonoprazan
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Terminal Phase Half-life (t1/2) of Vonoprazan
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Apparent Oral Clearance (CL/F) of Vonoprazan
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose
Apparent Volume of Distribution (Vz/F) of Vonoprazan
Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose

Results and safety

Results posted to the registry on 19 Dec 2025, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Vonoprazan 10 mg: Treatment Sequence 1	5	5
Vonoprazan 10 mg: Treatment Sequence 2	5	5
Vonoprazan 10 mg: Treatment Sequence 3	5	5
Vonoprazan 10 mg: Treatment Sequence 4	5	5
Vonoprazan 10 mg: Treatment Sequence 5	5	5

Primary outcome: Maximum Observed Drug Concentration (Cmax) of Vonoprazan

Time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose. Geometric mean (Geometric Coefficient of Variation). Unit: nanogram per milliliter (ng/mL)

Measure	Treatment A: Vonoprazan 10 mg n = 25	Treatment B: Vonoprazan 10 mg n = 25	Treatment C: Vonoprazan 10 mg n = 25	Treatment D: Vonoprazan 10 mg n = 25	Treatment E: Vonoprazan 10 mg n = 25
Value	6.11 (47.8)	5.81 (41.4)	5.46 (36.1)	5.72 (46.2)	5.40 (38.4)

Treatment A: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg: Ratio of GLSM Percentage (%): 113.26 (90% CI 104.86 to 122.33)
Treatment B: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg: Ratio of GLSM (%): 107.65 (90% CI 99.67 to 116.28)
Treatment C: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg: Ratio of GLSM (%): 101.19 (90% CI 93.68 to 109.30)

Population analysed: The Pharmacokinetic (PK) population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter.

Primary outcome: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan

Measure	Treatment A: Vonoprazan 10 mg n = 25	Treatment B: Vonoprazan 10 mg n = 25	Treatment C: Vonoprazan 10 mg n = 25	Treatment D: Vonoprazan 10 mg n = 25	Treatment E: Vonoprazan 10 mg n = 25
Value	57.1 (45.8)	54.8 (42.0)	52.8 (41.7)	51.7 (47.6)	49.8 (38.5)

Treatment A: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg: Ratio of GLSM (%): 114.62 (90% CI 107.46 to 122.24)
Treatment B: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg: Ratio of GLSM (%): 110.01 (90% CI 103.14 to 117.33)
Treatment C: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg: Ratio of GLSM (%): 106.00 (90% CI 99.39 to 113.06)

Population analysed: The PK population included participants who received at least 1 dose of study drug and had sufficient concentration data to support accurate estimation of at least 1 PK parameter.

Primary outcome: AUC From Time 0 Extrapolated to Infinity (AUC0-inf) of Vonoprazan

Measure	Treatment A: Vonoprazan 10 mg n = 25	Treatment B: Vonoprazan 10 mg n = 25	Treatment C: Vonoprazan 10 mg n = 25	Treatment D: Vonoprazan 10 mg n = 25	Treatment E: Vonoprazan 10 mg n = 25
Value	59.2 (44.3)	57.1 (39.4)	55.3 (39.0)	54.1 (44.9)	51.9 (36.3)

Treatment A: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg: Ratio of GLSM (%): 114.01 (90% CI 107.28 to 121.17)
Treatment B: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg: Ratio of GLSM (%): 109.99 (90% CI 103.49 to 116.90)
Treatment C: Vonoprazan 10 mg vs Treatment E: Vonoprazan 10 mg: Ratio of GLSM (%): 106.55 (90% CI 100.26 to 113.24)

6 secondary outcomes are reported in the full results.

Adverse events

Time frame: Day 1 to Day 28. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Treatment A: Vonoprazan 10 mg	0 of 25 (0%)	2 of 25 (8%)	0 of 25
Treatment B: Vonoprazan 10 mg	0 of 25 (0%)	0 of 25 (0%)	0 of 25
Treatment C: Vonoprazan 10 mg	0 of 25 (0%)	1 of 25 (4%)	0 of 25
Treatment D: Vonoprazan 10 mg	0 of 25 (0%)	1 of 25 (4%)	0 of 25
Treatment E: Vonoprazan 10 mg	0 of 25 (0%)	1 of 25 (4%)	0 of 25

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2025.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Individual participant dataSharing planned: No

Related trials for Healthy Volunteers

Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
RecruitingEarly Phase 1
Study Brain Mechanisms of Frustration With Magnetoencephalography in Healthy Volunteers
Irritability

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Medical Director study director

Phathom Pharmaceuticals

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Dec 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum Observed Drug Concentration (Cmax) of Vonoprazan (time frame: Day 1 of each 3-day treatment period: Within 15 minutes pre-dose and 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, and 48 hours post-dose). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06831344.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2025.